

January 18, 2026

DCS-CRD BSE Limited First Floor, New Trade Wing Rotunda Building, Phiroze Jeejeebhoy Towers Dalal Street, Fort Mumbai 400001 Fax No.2272 3121/2037/2039	Listing Compliance National Stock Exchange of India Limited Exchange Plaza, 5 th Floor Plot No. C/1, 'G' Block, Bandra- Kurla Complex Bandra East Mumbai 400051 Fax No.2659 8237/8238
Stock Code: 543213	Stock Code: ROSSARI

Dear Sir/Madam,

Subject.: Q3 & 9M FY26 Press Release

Please find enclosed a copy of the Press Release for the quarter and nine months ended December 31, 2025.

The same may please be taken on record and suitably disseminated to all concerned.

Thanking you,

Yours Sincerely,
For Rossari Biotech Limited



Parul Gupta
Head - Company Secretary & Legal
Membership No.: A38895

Encl.: as above

ROSSARI BIOTECH LIMITED

(An ISO 9001:2015 & 14001:2015 Certified Company) (CIN: L24100MH2009PLC194818)

Regd. Office: Rossari House, Golden Oak, LBS Marg, Surya Nagar, Opp. Mahindra Showroom, Vikhroli (West), Mumbai - 400079, Maharashtra, India. T: +91-22-6123 3800

Factory : Plot No. 10 & 11, Survey No. 90/1/10 & 90/1/11/1, Khumbharwadi, Village Naroli, Silvassa - 396235, Dadra & Nagar Haveli (U.T.), India. T: 0260-669 3000

: Plot No. D3-24-2 & D3-24-3, Phase III, GIDC Dahej, Village Galenda, Taluka Vagra, Bharuch, Gujarat - 392130, India. T: +91-2641-661621



Rossari Biotech Limited

Corporate Office: Rossari House, Golden Oak, LBS Marg, Surya Nagar, Opp. Mahindra Showroom, Vikhroli (West), Mumbai – 400079, Maharashtra, India

Rossari Biotech announces Q3 FY26 results

Q3 FY26

Revenues at Rs. 581.7 Cr, up 13% YoY
EBITDA at Rs. 68.9 Cr, up 6% YoY
PAT at Rs. 32.8 Cr, up 3% YoY

Mumbai, January 17, 2026: Rossari Biotech Limited (Rossari), a Specialty-Chemicals manufacturer providing intelligent and sustainable solutions for customers across industries, has announced its financial results for the quarter ended December 31, 2025.

Consolidated: Q3 FY26 performance overview compared with Q3 FY25

- Revenue from operations grew 13% to Rs. 581.7 crore as compared to Rs. 512.7 crore
- EBITDA improved by 6% to Rs. 68.9 crore from Rs. 64.8 crore
 - o EBITDA margin at 11.8% as against 12.6%
- PAT increased by 3% to Rs. 32.8 crore from Rs. 31.7 crore
- EPS (Diluted) stood at Rs. 5.9* as against Rs. 5.7*

Consolidated: 9M FY26 performance overview compared with 9M FY25

- Revenue from operations stood at Rs. 1,711.5 crore as against Rs. 1,500.7 crore, up 14%
- EBITDA increased by 7% to Rs. 208.7 crore as against Rs. 195.6 crore
 - o EBITDA margin at 12.2% as against 13.0%
- PAT higher by 1% to Rs. 103.2 crore as against Rs. 101.9 crore
- EPS (Diluted) stood at Rs. 18.6* as against Rs. 18.4*

Note:

- 1) All figures, unless mentioned otherwise, are on a consolidated basis
- 2) * EPS not annualized

Commenting on the performance, in a joint statement, Mr. Edward Menezes, Promoter & Executive Chairman, and Mr. Sunil Chari, Promoter & Managing Director, said

"We delivered healthy YoY growth in Q3 FY26 despite a softer domestic demand environment during the quarter. Consolidated revenues grew by 13% YoY, supported by a balanced contribution across business segments and continued traction in our international operations.

HPPC recorded a YoY growth of 11% during the quarter, reflecting stable demand amid a softer domestic environment. TSC delivered a growth of 18% YoY, while AHN grew by 39% YoY during the quarter, together providing support to overall growth. The diversified performance across segments helped offset moderation in select end-markets. Exports continued to support overall performance, driven by focused efforts to deepen relationships in key geographies and expand our customer base.

Profitability was impacted by ongoing investments in capacity expansion, product development and market-seeding initiatives. These investments are intended to strengthen our long-term competitive positioning, and we remain confident that operating leverage, scale benefits and an improving product mix will support margin improvement over time.

Our phased capacity expansion program across verticals continues to progress well, enhancing our manufacturing capabilities. Additionally, we are pleased to announce that the Board has granted in-principle approval to set up greenfield specialty chemicals manufacturing facilities in the Kingdom of Saudi Arabia (KSA). These expansions will support the strategic growth of the Company by improving supply capabilities, accelerating speed-to-market and strengthening the Company's position as a major player in manufacturing of specialty chemicals. The Project progress will be subject to customary evaluations and necessary regulatory / statutory approvals and is intended to be funded by way of equity, debt, internal accruals, or a combination of these financing means.

Looking ahead, we remain focused on disciplined execution, customer-led innovation and sustainable value creation. Supported by strong R&D capabilities and expanding capacities, we are well-positioned to navigate near-term volatility and deliver consistent, profitable growth for all our stakeholders."

Key Developments

Board grants in-principle approval for setting-up of greenfield manufacturing facilities in KSA

- Specialty Chemicals manufacturing facilities to be set up under Rossari International Limited Company, wholly owned subsidiary of the Company
- Aims to enhance supply chain resilience and accelerate speed-to-market
- The Company intends to explore available regional incentives and is evaluating optimal funding options for the project
- The Project progress will be subject to customary evaluations and necessary regulatory / statutory approvals

Note: Home, Personal Care and Performance Chemicals (HPPC); Textile Specialty Chemicals (TSC); Animal Health and Nutrition (AHN)

About Rossari Biotech Limited:

Rossari Biotech Limited (Rossari) (BSE: 543213, NSE: ROSSARI), is a Speciality-Chemicals manufacturer providing intelligent and sustainable solutions for customers across industries. Headquartered at Mumbai, India, the Company operates strategically located manufacturing facilities at Silvassa and Dahej. The Company offers tailor-made solutions for Home, Personal Care and Performance chemicals (HPPC), Textile speciality chemicals and Animal Health and Nutrition (AHN). With differentiated product offerings, Rossari caters to an array of applications across FMCG, Home care, Industrial Cleaning, Personal Care, Textile Speciality Chemicals, Performance Chemicals, the Animal Health and Nutrition and Pet Care businesses. The Company has an extensive and a dedicated network of distributors spread all over India.

For more information, please visit www.rossari.com OR contact:

Ketan Sablok

Rossari Biotech Limited
Tel: +91 22 6123 3800
Email: ketan.sablok@rossari.com

Anoop Poojari / Mitesh Jain

CDR India
Tel: +91 98330 90434 / 96194 44691
Email: anoop@cdr-india.com /
mitesh@cdr-india.com

DISCLAIMER:

Certain statements and opinions with respect to the anticipated future performance of Rossari Biotech Limited in the press release (“forward-looking statements”), which reflect various assumptions concerning the strategies, objectives and anticipated results may or may not prove to be correct. Such forward-looking statements involve a number of risks, uncertainties and assumptions which could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These include, among other factors, changes in economic, political, regulatory, business or other market conditions. Such forward-looking statements only speak as at the date the press release is provided to the recipient and Rossari Biotech Limited is not under any obligation to update or revise such forward-looking statements to reflect new events or circumstances. No representation or warranty (whether express or implied) is given in respect of any information in this press release or that this press release is suitable for the recipient’s purposes. The delivery of this press release does not imply that the information herein is correct as at any time subsequent to the date hereof and Rossari Biotech Limited has no obligation whatsoever to update any of the information or the conclusions contained herein or to correct any inaccuracies which may become apparent subsequent to the date hereof.